Click on image to view larger version.

Figure 1 The ARMYDA-PRO Study—Primary End Point

Incidence of primary end point (30-day major adverse cardiac events [MACE]) according to quartile distribution of pre-intervention platelet (P2Y12) reaction units (PRU) values. ARMYDA-PRO = Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome. Figure illustration by Rob Flewell.